期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

贝那普利联合缬沙坦治疗糖尿病肾病疗效观察 被引量：6

在线阅读 下载PDF
导出
摘要 糖尿病肾病（DN）是糖尿病最严重的并发症之一,是终末期肾功能衰竭的主要病因之一[1]。糖尿病一旦出现临床蛋白尿往往预后较差,因此尽早阻止蛋白尿的进一步发展,具有非常重要的意义。
作者 王红霞
机构地区 山东省临沂市交通医院
出处 《实用医技杂志》 2010年第10期962-963,共2页 Journal of Practical Medical Techniques
关键词 糖尿病肾病 疗效观察 贝那普利 缬沙坦 终末期肾功能衰竭 治疗 蛋白尿 并发症
分类号 R587.2 [医药卫生—内分泌]
  • 相关文献

参考文献7

  • 1Makino H,Nakamura Y,Wada J.Remission and regression of diabetic nephropathy.Hypertens Res,2003,26(7):515-519.
  • 2苏青,董艳,冯绮文,宋小君,邢惠莉,左静南.阻断肾素-血管紧张素系统对糖尿病大鼠肾脏蛋白激酶C活性的影响[J].中华内分泌代谢杂志,2003,19(2):133-135. 被引量：31
  • 3胡茂清,张执玉.糖尿病肾病的合理治疗[J].四川省卫生管理干部学院学报,2005,24(4):286-289. 被引量：6
  • 4陆菊明,潘长玉.巯甲丙脯酸治疗糖尿病伴蛋白尿[J].中华肾脏病杂志,1991,7(5):284-286. 被引量：5
  • 5Gilbert RE,Cox A,Wu LL,et al.Expression of transfor ming groth-factor-t31 and type Ⅳ collagen in the tubulointerstitrum in experimental diabetes effects of ACE inhibition.Diabets,1998,47(3):414-422.
  • 6Ulicna O,Cizova M,Kolesar P,et al.Bioenergetics of livermi-tochondria after administration of ramipril in experimental dia-bets mellitus.Bratisl Lek Listy,1997,98(12):687-691.
  • 7Lewis EJ,Hunsicker LG,Clarkew R,et al.Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropatay due to type 2 diabeters.N Engl J Med,2001,345(12):851-855.

二级参考文献25

  • 1Jerums G,Allen TJ,Campbell DJ,et al.Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria[J].American Journal of Kidney Diseases,2001;37(5):890.
  • 2Kuriyama S,Tomonari H,Tokudome G,et al.Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy[J].Hypertension Research-Clinical & Experimental,2002;25(6):849.
  • 3Rachmani R,Slavachevsky I,Amit M,et al.The effect of spironolactone,cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction:a randomized controlled study[J].Diabetic Medicine,2004;21(5):471.
  • 4Bolton WK,Cattran DC,Williams ME,et al.Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy[J].American Journal of Nephrology,2004;24(1):32.
  • 5Nakamura T,Ushiyama C,Suzuki S,et al.Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria[J].Diabetic Medicine,2001;18(4):308.
  • 6Iso K,Tada H,Kuboki K,et al.Long-term effect of epalrestat,an aldose reductase inhibitor,on the development of incipient diabetic nephropathy in Type 2 diabetic patients[J].Journal of Diabetes & its Complications,2001;15(5):241.
  • 7Gambaro G,Kinalska I,Oksa A,et al.Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients:the Di.N.A.S.randomized trial[J].Journal of the American Society of Nephrology,2002;13(6):1615.
  • 8Waugh,NR;Robertson,AM.Protein restriction for diabetic renal disease [J].The Cochrane Library,Copyright,2004;The Cochrane Collaboration Volume(4)
  • 9Fried LF,Orchard TJ,Kasiske BL.Effect of lipid reduction on the progression of renal disease:a meta-analysis[J].Kidney Int,2001;59(1):260.
  • 10Imanishi M,Yoshioka K,Okumura M,et al.Sodium sensitivity related to albuminuria appearing before hypertension in type 2 diabetic patients[J].Diabetes Care,2001;24(1):111.

共引文献35

同被引文献29

引证文献6

二级引证文献19

实用医技杂志
2010年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部